Search
Displaying 561–570 of 659 for “retinal diseases”
-
REGENXBIO’s Gene Therapy for Wet AMD Performing Encouragingly in Human Study
Research NewsUnlike current treatments requiring multiple injections, REGENXBIO’s gene therapy is administered as a one-time subretinal injection to the affected eye.
-
Acucela Enrolling Patients in Phase 3 Trial for Stargardt Disease Treatment
Research NewsThe Seattle biotech Acucela is now enrolling participants in its Phase 3 clinical trial for emixustat hydrochloride, an emerging oral drug for slowing vision loss in people with Stargardt disease, an inherited form of a macular degeneration.
-
Recording Available for Achromatopsia Teleconference Hosted by AGTC, Foundation, and Achroma Corp
Research NewsApplied Genetic Technologies Corporation (AGTC), Achroma Corp, and the Foundation Fighting Blindness hosted a one-hour teleconference on the condition. The call highlighted the difficulties patients have in getting a diagnosis for achromatopsia, the importance of genetic testing, and gene therapy clinical trials underway.
-
jCyte Stem-Cell Therapy Moves into Phase IIb Clinical Trial for RP
Research NewsBased on lab studies, researchers believe the treatment can preserve and potentially rescue the patient’s existing photoreceptors, thereby saving and possibly restoring vision.
-
Stem-Cell Therapy for Retinitis Pigmentosa Safe Thus Far in Early Human Study
Research NewsThe trial is one of the first-ever for a stem-cell-derived therapy for RP.
-
Research News
Dr. Weleber became the 10th recipient of the Foundation’s highest honor, named after FFB co-founder Lulie Gund, during the opening lunch of the VISIONS 2016 conference.
-
ARVO 2016: High-School Sophomore Finds Gene Mutation in Family with Choroideremia
Research NewsAditya A. Guru, 16, used whole exome sequencing (WES), an innovative genetic-screening technology, to find the mutation.
-
ARVO 2016: Emerging Drug Targets Toxic Build-Up in Stargardt Disease
Research NewsIn August 2015, the biotech company Alkeus launched a multi-center TEASE Phase II clinical trial for the drug ALK-001.
-
- Jun 12, 2026 - Jun 13, 2026
- 8:00 a.m. - 6:00 p.m. (CDT)
- 1201 Houston Street, Fort Worth, TX 76102
Foundation EventThe United in Vision 2026 conference unites two prestigious events—the Foundation Fighting Blindness VISIONS conference and the Retina International World Congress—into one extraordinary global gathering. Scheduled from Wednesday, June 10 to Saturday, June 13, 2026, at the Fort Worth Convention Center in Fort Worth, Texas, this premier event brings together individuals and families impacted by blinding retinal conditions, alongside leading researchers, clinicians, patient advocates, and industry partners, to foster collaboration, innovation, and hope.
-
Beacon Stories
Runner, storyteller, and community builder — Eavan O’Neill turned her Stargardt disease diagnosis into a mission to connect and uplift others through her own lived experiences. Through Brightside, she’s redefining what it means to live boldly and authentically with vision loss.
